ClinicalTrials.gg
CompletedNCT03329846Updated Jul 9, 2021Results posted

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

A Phase 3 interventional study of BMS-986205 and Nivolumab in Melanoma and Skin Cancer, sponsored by Bristol-Myers Squibb. Completed at 63 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-07-09.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.

Enrollment
59th of 75
20 · median 107
Started
2017
with 4 others
Phase 3
21 of 111
none open now
Registered
79th of 111
by date

Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 59th largest by enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2017, is one of 21 in phase 3, and was the 79th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Melanoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated

03

Conditions studied

  • Melanoma
  • Skin Cancer
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • 12 years and older unless not permitted by local regulations; in that case 18 years old and older
  • (ECOG) performance status of less than or equal to 1
  • confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
  • Treatment-naïve participants (no prior systemic anticancer therapy for unresectable or melanoma)
  • per v1.1

Exclusion criteria

Exclusion Criteria:

  • Active or
  • Uveal or ocular melanoma
  • Participants with active, known, or suspected disease
  • Prior active within the previous 3 years except for locally curable cancers that have been apparently cured

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Nivolumab + Placebo

    Specified dose on specified day Participants will no longer receive BMS-986205 Placebo

    Biological: Nivolumab · Drug: Placebo

  • Experimental
    Nivolumab + BMS-986205

    Specified dose on specified day. Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion

    Drug: BMS-986205 · Biological: Nivolumab

Interventions

  • DrugLinrodostatStudies of LinrodostatLinrodostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    specified dose on specified day

  • BiologicalNivolumab

    Specified dose on specified day

    Also known as: BMS-936558

  • DrugPlacebo

    Specified dose on specified day

    Also known as: BMS-986205 matching placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation

    Time frame: From first dose to 30 days following last dose (up to approximately 25 months)

07

Results

Posted Jul 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneNivolumab + BMS-986205Nivolumab
Started1010
Completed21
Not completed89
Withdrew: Disease progression46
Withdrew: Study drug toxicity10
Withdrew: Participant request to discontinue treatment01
Withdrew: Participant withdrew consent10
Withdrew: Other reasons22

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events

Number of participants experiencing different types of Adverse Events, including Death, Any cause Adverse Events (AEs), Drug-related AEs, Any cause Serious Adverse Events (SAEs), Drug-related SAEs, SAEs leading to discontinuation, and Drug-related Non-serious AEs leading to discontinuation

Time frame:
From first dose to 30 days following last dose (up to approximately 25 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsNivolumab + BMS-986205Nivolumab
Deaths00
Any cause SAEs (any grade)33
Drug-related SAEs (any grade)10
SAEs leading to discontinuation10
Any cause AEs (any grade)109
Drug-related AEs (any grade)97
Drug-Related Non-serious AEs leading to discontinuation00

Adverse events

Collected over All-cause mortality was assessed from first dose to approximately 300 days following last dose. Serious adverse events and non-serious adverse events above 5% were assessed from first dose to 100 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab + BMS-9862051/10 (10%)4/10 (40%)10/10 (100%)
Nivolumab3/10 (30%)4/10 (40%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventNivolumab + BMS-986205Nivolumab
ConstipationGastrointestinal disorders1/100/10
VomitingGastrointestinal disorders1/100/10
Gastroenteritis viralInfections and infestations1/100/10
Lower respiratory tract infectionInfections and infestations0/101/10
PneumoniaInfections and infestations0/101/10
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/101/10
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/101/10
Renal failureRenal and urinary disorders1/100/10
Pleural effusionRespiratory, thoracic and mediastinal disorders0/101/10
Most frequent other events
Showing 10 of 86
Most frequent other events
EventNivolumab + BMS-986205Nivolumab
NauseaGastrointestinal disorders5/104/10
AstheniaGeneral disorders5/102/10
Decreased appetiteMetabolism and nutrition disorders3/102/10
ArthralgiaMusculoskeletal and connective tissue disorders2/103/10
ConstipationGastrointestinal disorders2/101/10
DiarrhoeaGastrointestinal disorders1/102/10
VomitingGastrointestinal disorders1/102/10
FatigueGeneral disorders2/102/10
Influenza like illnessGeneral disorders2/101/10
Lower respiratory tract infectionInfections and infestations0/102/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nivolumab + BMS-986205NivolumabTotal
<=18 years000
Between 18 and 65 years4610
>=65 years6410
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab + BMS-986205NivolumabTotal
Female448
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab + BMS-986205NivolumabTotal
Hispanic or Latino011
Not Hispanic or Latino6511
Unknown or Not Reported448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab + BMS-986205NivolumabTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10818
More than one race000
Unknown or Not Reported011
08

Study locations

63 sites
  • Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • University Of Chicago
    Chicago, Illinois 60637, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Local Institution
    Seattle, Washington 98109, United States
  • Local Institution
    Blacktown, New South Wales 2148, Australia
  • Melanoma Institute Australia
    North Sydney, New South Wales 2146, Australia
  • Local Institution
    Greenslopes, Queensland 4120, Australia
  • Local Institution
    Woolloongabba, Queensland 4120, Australia
  • Local Institution
    Box Hill, Victoria 3128, Australia
  • Local Institution
    Melbourne, Victoria 3000, Australia
  • Local Institution
    Melbourne, Victoria 3004, Australia
  • Local Institution
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution
    Quebec, G1R 2J6, Canada
  • Klinika onkologie a radioterapie
    Hradec Kralove, 500 05, Czechia
  • Dermatovenerologicka klinika 3. LF UK a FNKV
    Praha 10, 100 34, Czechia
  • Dermatovenerologicka klinika VFN a 1. LF UK
    Praha 2, 128 08, Czechia
  • Local Institution
    Boulogne-billancourt, 92104, France
  • Local Institution
    Saint Etienne Cedex 2, 42055, France
  • Local Institution
    Villejuif Cedex, 94805, France
  • Elbe Klinikum Buxtehude
    Buxtehude, 21614, Germany
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Local Institution
    Essen, 45147, Germany
  • SRH Wald-Kliniken Gera GmbH
    Gera, Germany
  • Georg August Universitaet Goettingen
    Goettingen, 37075, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Heidelberg, 69120, Germany
  • Local Institution
    Muenchen, 80337, Germany
  • Local Institution
    Tuebingen, 72076, Germany
  • Interbalkan European Medical Center
    Thessaloniki, 57001, Greece
  • Local Institution
    Dooradoyle, Limerick, Ireland
  • Local Institution
    Dublin, 4, Ireland
  • Local Institution
    Dublin, 7, Ireland
  • Local Institution
    Milano, 20133, Italy
  • Istituto Nazionale Tumori Fondazione Pascale
    Napoli, 80131, Italy
  • Azienda Ospedaliera Universitaria Senese
    Siena, 53100, Italy
  • Local Institution
    Sendai-shi, Miyagi 9808574, Japan
  • Local Institution
    Niigata-shi, Niigata 9518566, Japan
  • Local Institution
    Okayama-shi, Okayama 7000914, Japan
  • Local Institution
    Osaka-shi, Osaka 5418567, Japan
  • Local Institution
    Chuo-ku, Tokyo 1040045, Japan
  • Local Institution
    Amsterdam, 1066 CX, Netherlands
  • Local Institution
    Groningen, 9700RB, Netherlands
  • Local Institution
    Nijmegen, 6525 GA, Netherlands
  • Local Institution
    Rotterdam, 3008 AE, Netherlands
  • Local Institution
    Christchurch, New Zealand
  • Local Institution
    Wellington, 6021, New Zealand
  • Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
    Warszawa, 02-781, Poland
  • Local Institution
    Barcelona, 08036, Spain
  • Local Institution
    Jaen, 23007, Spain
  • Local Institution
    Madrid, 28007, Spain
  • Local Institution
    Malaga, 29010, Spain
  • Local Institution
    Santiago Compostela, 15706, Spain
  • Local Institution
    Valencia, 46026, Spain
  • Universitaetsspital Zuerich
    Zürich, 8091, Switzerland
  • Local Institution
    London, Greater London SW17 0RE, United Kingdom
  • Local Institution
    London, Greater London SW3 6JJ, United Kingdom
  • Local Institution
    Belfast, BT9 7AB, United Kingdom
  • Local Institution
    Cambridge, CB2 0QQ, United Kingdom
  • Local Institution
    Cottingham, HU16 5JQ, United Kingdom
  • Local Institution
    Manchester, M20 4BX, United Kingdom
  • Local Institution
    Tauton, TA1 5DA, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jul 2020, 31 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 31 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 6, 2017
StartActual
Nov 30, 2017
Primary completionActual
Jul 2, 2020
CompletionActual
Jul 2, 2020
Results first posted
Jul 9, 2021
Last update
Jul 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03329846
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 30, 2017
Primary completion
Jul 2, 2020
Completion
Jul 2, 2020
Results posted
Jul 9, 2021
Last update
Jul 9, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linrodostat

Start the discussion